NCT00992342View on ClinicalTrials.gov

A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Healthy
Interventions
DRUG

PF-03893787

oral solution, 5 mg, QD for 14 days

DRUG

PF-03893787

oral solution, 15 mg, QD for 14 days

DRUG

PF-03893787

oral solution, 50 mg, QD for 14 days

Trial Locations (1)

1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY